October 09, 2008 – Finalist of the Ernest & Young Competition “Entrepreneur des Jahres 2008”

Alrise announces that its Chief Executive Officer and Founder Dr. Celal Albayrak was one of the finalist for the sought-after title of “Entrepreneur des Jahres 2008” (Entrepreneur of the Year 2008).

An independent jury awarded the winners in the categories Industry, Commerce, Service, Information and Communication Technology/Media, and Start-up. The winners were honoured at a solemn awards ceremony held in the Alte Oper in Frankfurt on October 09, 2008. Moreover, all finalists were decorated and accepted as a member of the “Entrepreneur des Jahres” club, the “Hall of Fame” for entrepreneurs in Germany.

____________________________________________________________________

July 16, 2008 - ALRISE Wins Backing of Industry Leader Dr. Giuseppe Vita

ALRISE Biosystems GmbH, the Berlin-based drug delivery specialist, announced that Dr. Giuseppe Vita has invested in the company.

„We are excited to have gained Dr. Vita, a leading expert in the pharmaceutical industry, as an additional investor in our company,” stated Dr. Celal Albayrak, CEO and founder of ALRISE. “As a long-standing CEO of Schering AG, Dr. Vita brings with him an exceptional reputation and extensive experience to support ALRISE in further establishing itself as a preferred pharmaceutical industry partner in the market for “controlled-release formulations”. Dr. Vita will assume the role of Director of the Scientific Advisory Board and actively brings his industry expertise into our young company.”

Dr. Vita states: “ALRISE possesses a highly innovative and worldwide patented technology platform with outstanding and unique attributes. In addition to its use for new formulations of active pharmaceutical ingredients, the ImSus® technology in particular answers the current demand for life-cycle management in the pharmaceutical industry.”

Micro particle depot formulations dramatically reduce the dosing frequency and achieve a steady pharmacokinetic profile for better tolerability, reduced side effects, and improved patient compliance. A critical factor leading to Dr. Vita’s investment was the fact that the ImSus® technology, in contrast to the competing methods, only uses non-toxic solvents. This leads to an improved product safety profile as well as a more straight-forward and faster approval process. In addition, the ImSus® technology is well suited for the formulation of biologicals such as proteins and peptides as well as small hydrophobic molecules as it considerably improves bioavail¬ability through microencapsulation.

Karlheinz Schmelig from Creathor Venture and Christian Seegers from IBB Beteiligungsgesellschaft stated: “We are very excited to gain a leading industry expert such as Dr. Giuseppe Vita for ALRISE Biosystems GmbH. With his experience and industry network he will surely make a meaningful contribution to ALRISE’s competitive positioning.”

_________________________________________________________________

ALRISE Biosystems GmbH
Robert-Roessle-Straße 10
Otto-Warburg-Haus
13125 Berlin, Germany
Phone +49 30.94 89 24 83
 Fax +49 30.94 89 24 82
info@alrise.de